<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04355455</url>
  </required_header>
  <id_info>
    <org_study_id>Citalopram MuMoS HV</org_study_id>
    <nct_id>NCT04355455</nct_id>
  </id_info>
  <brief_title>Effects of Serotonin Agonist Citalopram on Multimodal Esophageal Stimulation in Healthy Volunteers</brief_title>
  <official_title>Effects of Serotonin Agonist Citalopram on Multimodal Esophageal Stimulation in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the effect of citalopram, a selective serotonin reuptake inhibitor, on
      esophageal sensitivity.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in sensitivity to thermal stimulation</measure>
    <time_frame>After 1 hour 30 minutes after administration citalopram, we will start with the thermal stimulation</time_frame>
    <description>To detect changes in thermal stimulation for sensitivity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in sensitivity to mechanical stimulation</measure>
    <time_frame>After 1 hour 45 minutes after administration citalopram, we will start with the mechanical stimulation</time_frame>
    <description>To detect changes in mechanical stimulation for sensitivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sensitivity to electrical stimulation</measure>
    <time_frame>After 2 hours after administration citalopram, we will start with the electrical stimulation</time_frame>
    <description>To detect changes in electrical stimulation for sensitivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sensitivity to chemical stimulation</measure>
    <time_frame>After 2 hours 15 minutes after administration citalopram, we will start with the chemical stimulation</time_frame>
    <description>To detect changes in chemical stimulation for sensitivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in positive and negative affect score</measure>
    <time_frame>At the beginning of the study and at the end of the multimodal stimulation</time_frame>
    <description>To detect change in affect of the multimodal stimulation using the PANAS = Positive and Negative Affect scale that consists of two 10-item scales to measure both positive and negative affect. Higher score on the Positive scale is better; Higher score on the Negative Affect scale is worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in state trait and anxiety score</measure>
    <time_frame>At the beginning of the study and at the end of the multimodal stimulation</time_frame>
    <description>to detect changes in the score due to the multimodal stimulation using the The State-Trait Anxiety Inventory (STAI). Each type of anxiety has its own scale of 20 different questions that are scored.Scores range from 20 to 80, with higher scores correlating with greater anxiety.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Gastroesophageal Reflux</condition>
  <arm_group>
    <arm_group_label>Citalopram</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administration of citalopram to assess the esophageal sensitivity in HV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administration of placebo to assess the esophageal sensitivity in HV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Citalopram</intervention_name>
    <description>40 mg citalopram intravenously</description>
    <arm_group_label>Citalopram</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HV aged between 18 - 60 years

        Exclusion Criteria:

          -  history of psychiatric disease or a positive first degree psychiatric family history

          -  pregnancy or lactation

          -  concomitant administration of any centrally activating medication (anti-depressive
             medication, hypnotics, sedatives, anxiolytics, â€¦)

          -  medication affecting esophageal motility

          -  significant co-morbidities (neuromuscular, psychiatric, cardiovascular, pulmonary,
             endocrine, autoimmune, renal and hepatic)

          -  prior history of esophageal, gastric surgery or endoscopic anti-reflux procedure

          -  history of gastrointestinal disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 15, 2020</study_first_submitted>
  <study_first_submitted_qc>April 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2020</study_first_posted>
  <last_update_submitted>April 20, 2020</last_update_submitted>
  <last_update_submitted_qc>April 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitaire Ziekenhuizen Leuven</investigator_affiliation>
    <investigator_full_name>Prof Dr Jan Tack</investigator_full_name>
    <investigator_title>Prof Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

